



Aurobindo Pharma receives final approval for Fluconazole Tablets

Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fluconazole Tablets 50mg, 100mg, 150mg and 200mg.

Fluconazole Tablets is the generic version of Pfizer's Diflucan[®] tablets 50mg, 100mg, 150mg and 200mg and is indicated for the treatment of fungal infections.

This is Aurobindo's 80th ANDA approval from the USFDA.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/ product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations

Aurobindo Pharma Limited

Reg Off: Plot No. 2, Maitrivihar, Ameerpeth, Hyderabad

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com